|Bid||5.31 x 34100|
|Ask||5.39 x 2900|
|Day's Range||5.37 - 5.54|
|52 Week Range||2.08 - 7.10|
|Beta (5Y Monthly)||1.32|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 24, 2021 - Mar 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.64|
Falcon.io, a Cision company, highlights the opportunities and challenges that face marketers in 2021 and beyondCOPENHAGEN, Denmark, Dec.
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, today announced the successful completion of its acquisition by Endo International plc (Endo) for approximately $658.2 million in equity value.
DUBLIN, Dec. 2, 2020 /CNW/ -- Endo International plc (NASDAQ: ENDP) announced today that it completed the previously announced acquisition of BioSpecifics Technologies Corp.